GROWTH
Top line decelerating.
+2.3% YoY versus +8.3% prior. 3y CAGR +5.4%.
+2.3%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
2 of 4 legendary models say BUY ZTS — but Peter Lynch & Joel Greenblatt disagree.
What would legendary investors pay for ZTS?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Mixed — Zoetis Inc. has 81.8% ROE but D/E 3.69.
Financial story
Mixed — Zoetis Inc.'s 81.8% ROE is strong, but its 3.69 debt-to-equity is elevated.
Bottom line: ZTS splits the legendary models — 2 BUY, 0 HOLD, 2 AVOID, but earns a C sector grade (53/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
+2.3% YoY versus +8.3% prior. 3y CAGR +5.4%.
+2.3%Net margin 28.2% versus 26.9% prior (+1.4pp). Operating 38.0%.
28.2%P/E 13.2x — 60% below the 5y median of 32.8x. Forward 11.4x hints at EPS expansion next year.
13.2xZTS's P/E ratio is 13.7x. 5-year P/E history is in the financials tab.
2 of 4 legendary models say BUY. Full breakdown by investor and signal is in the valuation tab.
ZTS's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
ZTS is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
2 of 4 legendary investor models rate ZTS a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $143. See the per-investor fair-value table in the valuation tab.
How does ZTS compare?
See exactly where ZTS ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingZTS sits at #40 in Healthcare with a C grade (53/100).
